Literature DB >> 2566926

Biphasic relaxant curves to glyceryl trinitrate in rat aortic rings. Evidence for two mechanisms of action.

E Malta1.   

Abstract

The concentration-effect curve for the relaxant effects of glyceryl trinitrate (GTN) in rat aortic rings consisted of two phases with IC50 values of 0.1 microM for Phase I and 14 microM for Phase II. Incubation of tissues with oxyhaemoglobin or the induction of tolerance to GTN abolished responses occurring in Phase I but were without effect on Phase II relaxant responses. Both phases of the relaxant curve appeared to involve cyclic GMP since responses were (i) potentiated by the cyclic GMP phosphodiesterase inhibitor zaprinast (M & B 22948) and (ii) inhibited by methylene blue and LY83583, agents which inhibit soluble guanylate cyclase. The latter agents inhibited Phase I responses in a non-surmountable manner while Phase II responses were shifted to the right without effect on the maximal response. Neither phase of relaxation involved stimulation of the Na+/K+ ATPase pump since treatment of tissues with ouabain or K+-free solutions did not alter the GTN biphasic curve. Phase I relaxant responses to GTN resembled those to the endothelium-dependent relaxant acetylcholine, since oxyhaemoglobin and methylene blue were non-surmountable antagonists; however there was no cross tolerance to acetylcholine in GTN tolerant tissues. Phase II relaxant responses resembled those obtained with sodium nitroprusside (SNP) since neither oxyhaemoglobin nor the induction of tolerance to GTN altered the response to SNP. These results indicate that there are two distinct mechanisms of relaxation for GTN in rat aortic rings; however both mechanisms appear to involve cyclic GMP as the second messenger.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566926     DOI: 10.1007/BF00165149

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta.

Authors:  C R Molina; J W Andresen; R M Rapoport; S Waldman; F Murad
Journal:  J Cardiovasc Pharmacol       Date:  1987-10       Impact factor: 3.105

2.  Effects of glyceryl trinitrate on endothelium-dependent and -independent relaxation and cyclic GMP levels in rat aorta and human coronary artery.

Authors:  R M Rapoport; S A Waldman; R Ginsburg; C R Molina; F Murad
Journal:  J Cardiovasc Pharmacol       Date:  1987-07       Impact factor: 3.105

3.  Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.

Authors:  L J Ignarro; H Lippton; J C Edwards; W H Baricos; A L Hyman; P J Kadowitz; C A Gruetter
Journal:  J Pharmacol Exp Ther       Date:  1981-09       Impact factor: 4.030

4.  Different sensitivities of arteries and veins to glyceryltrinitrate-induced relaxation and tolerance: an "in vitro" study on isolated vessels from rabbits.

Authors:  R Rösen; E König; W Klaus
Journal:  Arch Int Pharmacodyn Ther       Date:  1987-02

5.  Nitroglycerine-induced biphasic relaxation in vascular smooth muscle of rat aorta.

Authors:  H Karaki; K Murakami; H Nakagawa; N Urakawa
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

6.  Relaxation of bovine mesenteric artery induced by glyceryl trinitrate is attenuated by pertussis toxin.

Authors:  J Ahlner; K L Axelsson; M Ekstram-Ljusegren; R L Friedman; N Grundström; J O Karlsson; R G Andersson
Journal:  Pharmacol Toxicol       Date:  1988-03

7.  Effects of atrial natriuretic factor, sodium nitroprusside, and acetylcholine on cyclic GMP levels and relaxation in rat aorta.

Authors:  R M Rapoport; S A Waldman; K Schwartz; R J Winquist; F Murad
Journal:  Eur J Pharmacol       Date:  1985-09-24       Impact factor: 4.432

8.  Effect of ouabain and alterations in potassium concentration on relaxation induced by sodium nitroprusside.

Authors:  R M Rapoport; F Murad
Journal:  Blood Vessels       Date:  1983

9.  Retention and subsequent liberation of glyceryl trinitrate in organ baths influences the relaxation of bovine mesenteric arteries contracted by various agents.

Authors:  J Ahlner; K L Axelsson; M E Ljusegren; B Norlander; R G Andersson
Journal:  Pharmacol Toxicol       Date:  1987-11
View more
  6 in total

1.  Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin.

Authors:  G Abou-Mohamed; W H Kaesemeyer; R B Caldwell; R W Caldwell
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  Mechanisms of action of nitrates.

Authors:  K E Torfgård; J Ahlner
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

3.  An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation.

Authors:  Zhiqiang Chen; Matthew W Foster; Jian Zhang; Lan Mao; Howard A Rockman; Toshihiro Kawamoto; Kyoko Kitagawa; Keiichi I Nakayama; Douglas T Hess; Jonathan S Stamler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

4.  Vasodilating properties of KRN2391: structural basis of a new pyridine-type potassium channel opener with a nitrate moiety.

Authors:  T Ishibashi; M Hamaguchi; S Imai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

5.  Comparative effects of activation of soluble and particulate guanylyl cyclase on cyclic GMP elevation and relaxation of bovine tracheal smooth muscle.

Authors:  S C Ijioma; R A Challiss; J P Boyle
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

6.  Formation of Nitric Oxide by Aldehyde Dehydrogenase-2 Is Necessary and Sufficient for Vascular Bioactivation of Nitroglycerin.

Authors:  Marissa Opelt; Emrah Eroglu; Markus Waldeck-Weiermair; Michael Russwurm; Doris Koesling; Roland Malli; Wolfgang F Graier; John T Fassett; Astrid Schrammel; Bernd Mayer
Journal:  J Biol Chem       Date:  2016-09-27       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.